CROs Relied Upon for Larger Studies: Results From KMR Group Outsourcing Performance Study
KMR Group
As outsourcing continues to be a key component of clinical trials, the ability to analyze the performance of CROs is of utmost importance to sponsor companies. KMR Group completed an analysis comparing the performance of outsourced versus internal trials, exploring how the CRO industry in general fares on a variety of key performance metrics for various outsourced services.
Figure 1. Trials with a wider scope-more than eight countries-tend to be outsourced more often than trials with fewer countries.
The Outsourcing Performance Study assessed recent Phase II and Phase III trials. About one-fifth of all trials are conducted internally, with no outsourcing. But geographic scope plays a role when deciding if there is a need to outsource. Trials with a wider scope—more than eight countries—tend to be outsourced more often than trials with fewer countries. There is no difference in the level of outsourcing for trials that are in fewer countries.
Given the reliance of outsourcing on trials with more complex geography, and the importance of these large scale studies to the success of sponsors, the question arises as to whether the performance is in line with industry standard trial performance benchmarks. The assessment answers these questions and offers the first framework for benchmarking outsourced studies. Nine biopharmaceutical companies participated in the study: AbbVie, AstraZeneca, Bayer HealthCare, Biogen Idec, Bristol-Myers Squibb, GlaxoSmithKline, Merck Research Laboratories, Roche, and UCB.
—KMR Group, https://kmrgroup.com.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
